Apollo Medical (AMEH) Upgraded to “Hold” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Apollo Medical (OTCMKTS:AMEH) from a sell rating to a hold rating in a report published on Wednesday morning.

According to Zacks, “Apollo Medical Holdings, Inc. engages in the provision of healthcare services. It offers integrated care, inpatient and physician alignment solutions. The company focuses on physicians providing high-quality medical care, population health management and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. Apollo Medical Holdings, Inc. is headquartered in Glendale, CA. “

Shares of OTCMKTS AMEH opened at $16.45 on Wednesday. Apollo Medical has a 12 month low of $5.50 and a 12 month high of $30.00.

Apollo Medical (OTCMKTS:AMEH) last issued its quarterly earnings results on Tuesday, August 14th. The healthcare company reported $0.07 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.10 by ($0.03). The business had revenue of $123.01 million during the quarter.

In other news, insider Adrian Vazquez sold 25,000 shares of Apollo Medical stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $17.35, for a total transaction of $433,750.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Warren Hosseinion sold 22,000 shares of Apollo Medical stock in a transaction that occurred on Monday, August 20th. The stock was sold at an average price of $18.10, for a total value of $398,200.00. The disclosure for this sale can be found here. Insiders have sold a total of 196,474 shares of company stock worth $3,249,480 in the last three months.

A number of hedge funds have recently made changes to their positions in the stock. Strs Ohio acquired a new stake in Apollo Medical in the 2nd quarter valued at $186,000. Tiedemann Advisors LLC boosted its stake in Apollo Medical by 85.7% in the 1st quarter. Tiedemann Advisors LLC now owns 19,500 shares of the healthcare company’s stock valued at $311,000 after buying an additional 9,000 shares in the last quarter. Voya Investment Management LLC acquired a new stake in Apollo Medical in the 2nd quarter valued at $247,000. California Public Employees Retirement System acquired a new stake in Apollo Medical in the 2nd quarter valued at $322,000. Finally, Rhumbline Advisers acquired a new stake in Apollo Medical in the 2nd quarter valued at $571,000.

About Apollo Medical

Apollo Medical Holdings, Inc is a patient-centered, physician-centric integrated population health management company working to provide coordinated, outcomes-based medical care. The Company operates in healthcare delivery segment. Its operations include Hospitalists, which include its contracted physicians focusing on the delivery of medical care to hospitalized patients; an accountable care organization (ACO), which focuses on providing care to Medicare fee-for-service patients; an independent practice association (IPA), which contracts with physicians and provides care to Medicare, Medicaid, commercial and dual-eligible patients on a risk- and value-based fee basis; approximately three clinics, which it owns or operates, and which provide specialty care in the greater Los Angeles area, and Palliative care, home health and hospice services, which include its at-home and end-of-life services.

See Also: Hedge Funds

Get a free copy of the Zacks research report on Apollo Medical (AMEH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apollo Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Intesa Sanpaolo  Given a €2.90 Price Target at Goldman Sachs Group
Intesa Sanpaolo Given a €2.90 Price Target at Goldman Sachs Group
AGNC Investment  Given “Hold” Rating at Barclays
AGNC Investment Given “Hold” Rating at Barclays
Apollo Medical  Upgraded to “Hold” at Zacks Investment Research
Apollo Medical Upgraded to “Hold” at Zacks Investment Research
Aroundtown  Given a €7.55 Price Target at Nord/LB
Aroundtown Given a €7.55 Price Target at Nord/LB
HSBC Analysts Give BNP Paribas  a €58.00 Price Target
HSBC Analysts Give BNP Paribas a €58.00 Price Target
DELEK Grp Ltd/ADR  Upgraded to “Hold” at ValuEngine
DELEK Grp Ltd/ADR Upgraded to “Hold” at ValuEngine


Leave a Reply

© 2006-2018 Ticker Report. Google+.